Global Drug-Eluting Stents Market

Global Drug-Eluting Stents Market

  • November 2020 •
  • 127 pages •
  • Report ID: 5983281 •
  • Format: PDF
Report Scope:
This report examines the current and projected market potential of drug-eluting stents.It offers a detailed analysis of the regulatory scenario, competitive environment, pipeline, technological advancement, drivers, restraints and market growth trends.

The report also includes market projections through 2024 and the market rank for key market players. The report details the market share of drug-eluting stents based on types of product, application and end user.

By product type, the market is segmented into polymer-based drug-eluting stents and polymer-free drug-eluting stents.By application, the market is segmented into coronary artery disease (CAD) and peripheral artery disease (PAD).

By end user, the market is segmented into hospitals, ambulatory surgical centers and specialty centers and clinics.

By geography, the market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa. Detailed analyses of major countries such as the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India are covered in regional segments. For market estimates, data is provided for 2018 as the base year, 2019 and forecast through year-end 2024. Estimated values used are based on drug-eluting stent manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

Report Includes:
- 20 data tables and 18 additional tables
- An overview of global market for drug-eluting stents within the medical devices industry
- Estimation of the market size and analyses of market trends, with data from 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024
- Market share analysis of the drug-eluting stents based on product, application, end-use, and region
- Identification of segments with high growth potential and analysis of future applications of each of the segments
- Assessment of market dynamics for drug-eluting stents with market drivers and restraints explained, medical device regulations, market background and pipeline analysis of the stents
- Coverage of prevalence and epidemiology of cardiovascular disease and description of coronary artery disease (CAD) and peripheral artery disease (PAD)
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Company profiles of the leading market players, including Abbott, B. Braun Melsungen AG, Biotronik SE & Co. KG, Boston Scientific Corp., Medtronic Plc and Cook Medical Inc.

Summary:
The global market for drug-eluting stents was valued at REDACTED in 2018.The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach REDACTED by 2024.

Global market growth is attributed to the growing prevalence of cardiovascular diseases, a rise in the world’s geriatricpopulation and a growing demand for minimally invasive procedures.

There has been remarkable growth in the development of coronary stents to avoid restenosis and thrombosis.Improvements include progress in the design and conformation of metallic or resorbable structures, with an adequate balance between trackability and radial force.

Also noted is the development of antiproliferative drugs and polymers to control release and allow adequate endothelialization and optimal duration of the antiplatelet regimen.These developments led to growth in the drug-eluting stent market over the forecast period.

DES use rates escalated rapidly, quickly reaching about REDACTED of total stent use in the U.S. and some European countries.

Drug-eluting stents are coated with a drug and polymer, designed to allow for controlled and consistent release of the drug from the stent surface into the artery walls. Both the amount of drug and release rate has been determined so that healing can occur while allowing the processes leading to restenosis to be minimized, reducing the need for additional treatment in the stented area.

Rising incidence of CVD, heart failure and coronary heart disease cases come with growing prevalence of obesity, diabetes and high blood pressure, globally.These phenomena are anticipated to fuel drugeluting stents market growth over the forecast period.

According to the WHO, in 2016, an estimated REDACTED people died from CVD, signifying REDACTED of all global deaths.